(Q42988277)

12 November 2017

Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice (English)

1 reference

12 November 2017

1 reference

21

Kazuaki Chayama

1 reference

12 November 2017

3

Michio Imamura

1 reference

12 November 2017

11

Hiroshi Aikata

1 reference

12 November 2017

9

Masataka Tsuge

1 reference

12 November 2017

12

Shoichi Takahashi

1 reference

12 November 2017

13

Hidenori Ochi

1 reference

12 November 2017

4

C Nelson Hayes

1 reference

12 November 2017

2

Nobuhiko Hiraga

1 reference

12 November 2017

Niu Shi

1

1 reference

12 November 2017

Yizhou Zhang

5

1 reference

12 November 2017

Keiichi Kosaka

6

1 reference

12 November 2017

Akihito Okazaki

7

1 reference

12 November 2017

Eisuke Murakami

8

1 reference

12 November 2017

Hiromi Abe

10

1 reference

12 November 2017

Chise Tateno-Mukaidani

14

1 reference

12 November 2017

Katsutoshi Yoshizato

15

1 reference

12 November 2017

Hirotaka Matsui

16

1 reference

12 November 2017

Akinori Kanai

17

1 reference

12 November 2017

Toshiya Inaba

18

1 reference

12 November 2017

Fiona McPhee

19

1 reference

12 November 2017

Min Gao

20

1 reference

12 November 2017

language of work or name

English

0 references

publication date

15 January 2013

1 reference

12 November 2017

1 reference

12 November 2017

62

1 reference

12 November 2017

7

1 reference

12 November 2017

1055-1061

1 reference

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

12 November 2017

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Future hepatitis C virus treatment: interferon-sparing combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Hepatitis C virus replication in mice with chimeric human livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

'Touchdown' PCR to circumvent spurious priming during gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Near completely humanized liver in mice shows human-type metabolic responses to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Production of Infectious Hepatitis C Virus of Various Genotypes in Cell Cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Fast and accurate long-read alignment with Burrows-Wheeler transform

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-302600

10.1136/GUTJNL-2012-302600

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference